Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:PHVS

Pharvaris Q4 2025 Earnings Report

Pharvaris logo
$31.61 -0.30 (-0.95%)
As of 11:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pharvaris EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.69
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q4 2025
Date
4/3/2026
Time
Before Market Opens
Conference Call Date
Thursday, April 9, 2026
Conference Call Time
12:30PM ET

Upcoming Earnings

Pharvaris' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Pharvaris' Q4 2025 Press ReleasePress Release
(6-K)
Pharvaris' Q4 2025 Annual reportAnnual report
(20-F)
Pharvaris' Q4 2025 Annual reportAnnual report

Pharvaris Earnings Headlines

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
September 29 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063180
Pharvaris (NASDAQ:PHVS) Stock: Insider Johannes Gerardus Chri Schikan Sells 800 Shares
September 26 at 6:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053326
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
September 29 at 1:00 AM  |  Profits Run (Ad)
Pharvaris (NASDAQ:PHVS) Director Viviane Monges Sells 11,969 Shares of Stock
September 26 at 5:39 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053185
Pharvaris (NASDAQ:PHVS) CFO David Nassif Sells 6,000 Shares
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044779
Johannes Gerardus Chri Schikan Sells 200,000 Shares of Pharvaris (NASDAQ:PHVS) Stock
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041657
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks. The program is designed to provide patients with an oral alternative to currently available injectable or infused therapies.

The company has conducted clinical development activities in the United States, Europe and other international markets. Pharvaris’ leadership team includes Chief Executive Officer Berndt Modig, who has experience in the biotechnology and pharmaceutical industries. Deucrictibant remains an investigational product, and Pharvaris’ development programs are subject to the review and approval of regulatory authorities.

View Pharvaris Profile
Earnings Tools